Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma

BMC Cancer

Jing Han¹  Toshio Fujisawa²  Syed R Husain¹  Raj K Puri¹ 

[1] Tumor Vaccines and Biotechnology Branch, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, NIH Bldg 29B, Rm 2NN20, 29 Lincoln Dr., Bethesda, MD, 20892, USA

[2] Current address: Department of Gastroenterology, NTT Medical Center Tokyo, Tokyo, Japan

关键词: Salivary gland malignant neoplasms;    CD44;    CD24;    Stem-like cells;    neck squamous cell carcinoma);    HNSCC (head &;   

Others  :  858983
DOI  :  10.1186/1471-2407-14-173

 received in 2013-07-14, accepted in 2014-02-26,  发布年份 2014

【 摘 要 】

Background

Current evidence suggests that initiation, growth, and invasion of cancer are driven by a small population of cancer stem cells (CSC). Previous studies have identified CD44+ cells as cancer stem cells in head and neck squamous cell carcinoma (HNSCC). However, CD44 is widely expressed in most cells in HNSCC tumor samples and several cell lines tested. We previously identified a small population of CD24+/CD44+ cells in HNSCC. In this study, we examined whether this population of cells may represent CSC in HNSCC.

Methods

CD24+/CD44+ cells from HNSCC cell lines were sorted by flow cytometry, and their phenotype was confirmed by qRT-PCR. Their self-renewal and differentiation properties, clonogenicity in collagen gels, and response to anticancer drugs were tested in vitro. The tumorigenicity potential of CD24+/CD44+ cells was tested in athymic nude mice in vivo.

Results

Our results show that CD24+/CD44+ cells possessed stemness characteristics of self-renewal and differentiation. CD24+/CD44+ cells showed higher cell invasion in vitro and made higher number of colonies in collagen gels compared to CD24-/CD44+ HNSCC cells. In addition, the CD24+/CD44+ cells were more chemo-resistant to gemcitabine and cisplatin compared to CD24-/CD44+ cells. In vivo, CD24+/CD44+ cells showed a tendency to generate larger tumors in nude mice compared to CD24-/CD44+ cell population.

Conclusion

Our study clearly demonstrates that a distinct small population of CD24+/CD44+ cells is present in HNSCC that shows stem cell-like properties. This distinct small population of cells should be further characterized and may provide an opportunity to target HNSCC CSC for therapy.

【 授权许可】

   
2014 Han et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Mannelli G, Gallo O: Cancer stem cells hypothesis and stem cells ion head and neck cancers. Cancer Treat Rev 2012, 38:515-539.
• [2]Goon PKC, Stanley MA, Ebmayer J, Steinstrsässer L, Upile T, Jerjes W, Bernall-Sprekelsen M, Görner M, Sudhoff HH: HPV & head and neck cancer: a descriptive update. Head Neck Oncol 2009, 1:36. BioMed Central Full Text
• [3]Marur S, Forastiere AA: Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc 2008, 83:489-501.
• [4]Nguyen LV, Vanner R, Dirks P, Eaves CJ: Cancer stem cells: an evolving concept. Nat Rev Cancer 2012, 12:133-143.
• [5]Reya T, Morrison SJ, Clarke MF, Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 2011, 414:105-111.
• [6]Huntly BJP, Gilliland DG: Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev 2005, 5:311-321.
• [7]Singh S, Hawkins C, Clarke ID, Squire JA, Bayanl J, Hide T, Henkelman RM, Cusimano MD, Dirks PB: Identification of human brain tumor initiating cells. Nature 2004, 432:396-401.
• [8]Yeung TM, Gradhi SC, Wilding JL, Muschel R, Bodmer WF: Cancer stem cells from colorectal cancer-derived cell lines. PNAS 2009, 107:3722-3727.
• [9]Gao MQ, Choi YP, Kang S, Houn JH, Cho NH: CD24+ cells from hierarchically organized ovarian cancer are enriched in cancer stem cells. Oncogene 2010, 29:2697-80.
• [10]Overdevest JB, Thomas S, Kristiansen G, Hansel DE, Smith SC, Theodorescu D: CD24 offers a therapeutic target for control of bladder cancer metastasis based on a requirement for lung colonization. Cancer Res 2011, 71:3802-3811.
• [11]Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM: Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
• [12]Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE: Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. PNAS 2007, 104:973-978.
• [13]Lessard J, Sauvageaun G: Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 2003, 423:255-260.
• [14]Park IK, Morrison SJ, Clarken MF: Bmi1, stem cells, and senescence regulation. J Clin Invest 2004, 113:175-179.
• [15]Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC: Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2007, 36:594-603.
• [16]Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC, Ku HH, Chiou SH, Lo WL: Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophy Res Commun 2009, 385:307-313.
• [17]Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, Wicha MS, Prince ME: Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck 2010, 32:1195-1201.
• [18]Alberts AE, Chen C, Koberle B, Qian X, Klussmann JP, Wollenberg B, Kaufmann AM: Stem cells in squamous head and neck cancer. Crit Rev Oncol/Hemoatol 2012, 81:224-240.
• [19]Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, Sleeman JP: CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 2005, 65:10783-10793.
• [20]Oliveira LR, Oliveira-Costa JP, Araujo IM, Soave DF, Zanetti JS, Soares FA, Zucoloto S, Ribeiro-Silva A: Cancer stem cell immunophentypes in oral squamous cell carcinoma. J Oral Path Med 2011, 40:135-142.
• [21]Han J, Kioi M, Chu WS, Kasperbauer JL, Strome SE, Puri RK: Identification of potential therapeutic targets in human head & neck squamous cell carcinoma. Head Neck Oncol 2009, 1:27. BioMed Central Full Text
• [22]Kawakami K, Leland P, Puri RK: Structure, function, and targeting of interleukin 4 receptors on human head and neck cancer cells. Cancer Res 2000, 60:2981-2987.
• [23]Han J, Daniel JC: Biosynthesis of type VI collagen by glioblastoma cells and possible function in cell invasion of three-dimension matrices. Connect Tissue Res 1995, 31:161-170.
• [24]Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogen 2012, 31:1869-1883.
• [25]Mini E, Nobili S, Caciagli B, Landini I, Mazzei T: Cellular pharmacology of gemcitabine. Ann Oncol 2006, 17:v7-v12.
• [26]Dean M, Fojo T, Bates S: Tumor stem cells and drug resistance. Nat Rev 2005, 5:275-284.
• [27]Hu G, Li F, Ouyang K, Xie F, Tang X, Wang K, Han S, Jiang Z, Zhu M, Wen D, Qin X, Zhang L: Intrinsic gemcitabine resistance in a novel pancreatic cancer cell line is associated with cancer stem cell-like phenotype. Int J Oncol 2012, 40:798-806.
• [28]Bhattacharya B, Milura T, Brandenberger R, Mejido J, Luo Y, Yang AX, Joshi BH, Ginis I, Thies RS, Amit M, Lyons I, Condie BG, Itskovitz-Eldor J, Rao MS, Puri RK: Gene expressions in human embryonic stem cell lines: unique molecular signature. Blood 2004, 103:2956-2964.
• [29]Shackleton M, Vaillsny F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labbat ML, Wu L, Lindeman GJ, Visvader JE: Generation of a functional mammary gland from a single stem cell. Nature 2006, 439:84-88.
• [30]Soave DF, da Costa JPO, de Silveira GG, Ianez RC, de Oliveira LR, Lourenco SV, Ribeiro-Silva A: CD44/CD24 immunophenotypes on clinicopathologic features of salivary glands malignant neoplasms. Diagn Pathol 2013, 8:29. BioMed Central Full Text
• [31]Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Peterson I: CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 2003, 9:4906-4913.
• [32]Kristiansen G, Pilarsky C, Pervan J, Stürzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, Dietel M: CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 2004, 58:183-192.
• [33]Stuelten CH, Mertins S, Busch JI, Gowens M, Scudiero DA, Burkett MW, Hite KM, Alley M, Hollingshead M, Shoemaker RH, Niederhuber JE: Complex display of putative tumor stem cell markers in the NCI60 tumor cell line panel. Stem Cell 2010, 28:649-660.
• [34]Choi D, Lee HW, Hur KY, Kim JJ, Park GS, Jang SH, Song YS, Jang KS, Paik SS: Cancer stem cell markers CD133 and CD24 correlated with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009, 15:2258-2264.
• [35]Ghani FI, Yamazaki H, Iwata S, Okamoto T, Aoe K, Okabe K, Mimura Y, Fujimoto N, Kishimoto T, Yamada T, Xu CW, Morimoto C: Identification of cancer stem cell markers in human malignant mesothelioma cells. Biochem Biophy res Comm 2011, 404:735-742.
• [36]Pries R, Wittkope N, Trenkle T, Nitsch SM, Wollenberg B: Potential stem cell marker CD44 is constitutively expressed in permanent cell lines of head and neck cancer. In vivo 2008, 22:89-92.
• [37]Mack B, Gires O: CD44s and CD44v6 expression in head and neck epithelia. PlosOne 2008, 3:10.
• [38]Liebertz DJ, Lechner MG, Masood R, Sinha UK, Han J, Puri RK, Correa AJ, Epstein AL: Establishment and characterization of a novel head and neck squamous cell carcinoma cell line USC-HN1. Head Neck Oncol 2010, 2:5. BioMed Central Full Text
• [39]Chaffer CL, Bruechmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO, Brooks M, Reinhardt F, Su Y, Polyak K, Arendt LM, Kuperwasser C, Bierie B, Weinberg RA: Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. PNAS 2011, 108:7950-7955.